Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
HeartWare Reports Third Quarter 2012 Results
- International Revenue Growth of 40% Highlights Third Quarter Performance -

FRAMINGHAM, Mass. and SYDNEY, Nov. 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $22.9 million for the third quarter ended September 30, 2012, compared to revenue of $21.3 million for the same period of 2011.  Revenue from international markets increased approximately 40% to $19.2 million in the third quarter of 2012, from $13.7 million in the third quarter of 2011.  U.S. revenue, which is presently derived from clinical trial activities, was $3.7 million in the third quarter of 2012, compared to $7.6 million in the third quarter of 2011, due to the completed enrollment of the Company's Destination Therapy clinical trial in the second quarter of this year.  Currency fluctuations decreased revenue by nine percent in the third quarter compared to the same period in 2011.

For the nine months ended September 30, 2012, revenues increased approximately 31% to $78.3 million, compared to $59.7 million in the first nine months of 2011, supported by 60% commercial revenue growth internationally.  Currency fluctuations decreased revenue by seven percent compared to the same period in 2011. 

"We are pleased to have maintained strong international growth, particularly during the summer months of Europe, as 214 HeartWare® Ventricular Assist Systems were sold outside the U.S. in the third quarter of 2012, a 51% increase compared to 142 in the third quarter of last year," noted Doug Godshall, President and Chief Executive Officer.  "With the completion of enrollment in our Destination Therapy study in the United States, domestic revenue was primarily limited to the remaining slots in the Continued Access Protocol in the Bridge-to-Transplant indication.  As a result, 42 of the 256 global units sales generated during the third quarter of 2012 were from the U.S.  Globally more than 2,500 patients have now received the HeartWare System at one of the 103 international hospital sites or 50 clinical sites in the U.S.

"Following the positive recommendation of the Circulatory System Devices Advisory Committee in the second quarter, we have been focused on working with the FDA as it finalizes its review of our Premarket Approval (PMA) application for U.S. commercialization of the HeartWare Ventricular Assist System as a bridge to heart transplantation," added Mr. Godshall.  "Our team has been diligent in preparation for anticipated launch, and we look forward to the opportunity to advance the global commercialization of the HeartWare System and HVAD® Pump."

Total operating expenses for the third quarter of 2012 were $35.1 million, as compared to $23.5 million in the same period of 2011.  Research and development expense was $21.4 million for the third quarter of 2012, as compared to $12.7 million in the same period of 2011.  Increased development costs are a result of continuing clinical trial costs and research and development costs related to advancing HeartWare's pipeline technologies, including the MVAD® platform and a fully implantable system, as well as other early research initiatives. 

Selling, general and administrative expenses were $13.8 million in the third quarter of 2012, compared to $10.8 million in the third quarter of 2011.  The increase in selling, general and administrative expenses is related to continued growth supporting commercial activity outside of the U.S., preparation for anticipated commercial launch in the U.S., and an overall increase in corporate infrastructure to support the Company's rapid growth. 

Net loss for the third quarter of 2012 was $25.0 million, or a $1.75 loss per basic and diluted share, compared to a $14.0 million net loss, or a loss of $1.00 per basic and diluted share, in the third quarter of 2011.  For the nine months ended September 30, 2012, the Company recorded a net loss of $66.6 million, or a $4.70 loss per basic and diluted share, compared to a $33.5 million net loss, or a loss of $2.41 per basic and diluted share, in the first nine months of 2011.

At September 30, 2012, the Company had $117.6 million of cash, cash equivalents and investments.

HeartWare will host a conference call on Friday, November 9, 2012 at 8:00 a.m. U.S. Eastern Daylight Time to discuss the Company's financial results, highlights from the quarter and business outlook.  The call may be accessed by dialing 1-877-941-1428 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9665.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Third Quarter 2012 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE®, HVAD®, MVAD® and HeartWare logos are registered trademarks of HeartWare, Inc.

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of clinical trials, the presentation of clinical trial data, expected timing of regulatory filings and approvals, commercialization planning and research and development activities. Management believes that these forward-looking statements are reasonable as and when made.  However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.  HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility the FDA does not approve the marketing of the HeartWare® Ventricular Assist System in the U.S., and those described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.  We may update our risk factors from time to time in Part II, Item 1A."Risk Factors" in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

 

- Tables to Follow-

 

 

 

HEARTWARE INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

 


Three Months Ended

September 30,


Nine Months Ended

September 30,



2012


2011


2012


2011











Revenue, net

$   22,862


$   21,340


$    78,261


$    59,704


Cost of revenue

10,925


7,884


34,418


23,392


Gross profit

11,937


13,456


43,843


36,312











Operating expenses:









Selling, general and administrative

13,768


10,833


40,687


29,389


Research and development

21,379


12,705


61,392


32,285


Total operating expenses

35,147


23,538


102,079


61,674











Loss from operations

(23,210)


(10,082)


(58,236)


(25,362)











Other expense, net

(1,776)


(3,882)


(8,377)


(8,129)


Net loss

$    (24,986)


$    (13,964)


$  (66,613)


$  (33,491)











Net loss per common share — basic and diluted

$       (1.75)


$       (1.00)


$      (4.70)


$      (2.41)











Weighted average shares outstanding — basic and diluted

14,274


13,948


14,185


13,924






















 

HEARTWARE INTERNATIONAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)




September 30, 2012


December 31, 2011





ASSETS




Current assets:




Cash and cash equivalents

$          111,883


$          71,257

Short-term investments, net

5,743


91,925

Accounts receivable, net

16,919


14,953

Inventories, net

38,654


32,005

Prepaid expenses and other current assets

6,237


4,507

Total current assets

179,436


214,647

Property, plant and equipment, net

19,413


18,325

Other assets, net

13,164


7,760

Total assets

$        212,013


$        240,732





LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:




Accounts payable

$            9,374


$            5,025

Other accrued liabilities

15,622


12,436

Total current liabilities

24,996


17,461

Convertible senior notes, net

98,737


94,277

Other long-term liabilities

4,140


2,210

Stockholders' equity

84,140


126,784

Total liabilities and stockholders' equity

$          212,013


$        240,732

 

 

SOURCE HeartWare International, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
More and more enterprises today are doing business by opening up their data and applications through APIs. Though forward-thinking and strategic, exposing APIs also increases the surface area for potential attack by hackers. To benefit from APIs while staying secure, enterprises ...
Web conferencing in a public cloud has the same risks as any other cloud service. If you have ever had concerns over the types of data being shared in your employees’ web conferences, such as IP, financials or customer data, then it’s time to look at web conferencing in a private...
Many cloud hosting providers have achieved ticket-of-entry credibility in the data warehousing industry by building simple colocation centers. A first-tier database as a service (DBaaS) contender, however, is set apart by a value-added service approach that is strategic, consulta...
Today’s hyper competitive environment defined by unreasonable demands for speed and high expectations for quality and usability has forced companies to differentiate based on their technology. Every company is a software company where customers’ demands for features and functions...
Next-Gen Cloud. Whatever you call it, there’s a higher calling for cloud computing that requires providers to change their spots and move from a commodity mindset to a premium one. Businesses can no longer maintain the status quo that today’s service providers offer. Yes, the con...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News
Parsons is pleased to announce that it has acquired Secure Mission Solutions, a premier provider of ...